U.S. regulators have issued warnings to 18 websites that were selling fake or unapproved versions of Botox and similar wrinkle-relaxing injections. The UK government on Thursday announced plans to ...

Botulinum Toxin Type A has become a pivotal agent in modern dermatology, finding applications that range from the correction of dynamic rhytides to adjunctive procedures in surgical settings.

Expert Rev Neurother. 2009;9(12):1713-1725. The first patients with squint were successfully treated in 1977 [17] and since then botulinum toxin type A delivered by local injection has been used in ...

Enterococci are hardy microbes that thrive in the gastrointestinal tracts of nearly all land animals, including our own, and generally cause no harm. But their ruggedness has lately made them leading ...

The use of toxin botulinum-A is one of the most rapidly growing areas in cosmetic dermatology. There is always news about this incredible substance. There are new indications, new techniques, and new ...

A second type of Botulinum toxin - type B (brand name Myobloc®) -- may be as effective as type A (brand name Botox®) for the treatment of facial wrinkles, according to UCSF researchers. The study, ...

Add Yahoo as a preferred source to see more of our stories on Google. A sign for Botox, fillers and facial treatments in Lafayette, Calif. (Smith Collection/Getty Images) (Smith Collection/Gado via ...

Botulinum toxin type A (BTX-A) has emerged as a promising agent in both scar management and wound healing. By inducing temporary muscular paralysis, BTX-A reduces tension across wound edges, thereby ...

Please provide your email address to receive an email when new articles are posted on . Some botulinum toxin type A injection formulations have a faster onset, whereas others were shown to last longer ...

When I say I’ve been getting Botox my entire adult life, I’m not exaggerating one bit—I started at the ripe, young age of 19 to help prevent wrinkles from forming, and I’ve honestly never looked back.

CHICAGO, IL—The use of botulinum toxin type A in patients undergoing cardiac surgery does not seem to reduce the rate of postoperative atrial fibrillation (AF) overall, according to the phase II NOVA ...